The world is experiencing a huge wave of infection with the Omicron variant of SARS-CoV-2, and current vaccines and EUA-approved antibodies offer diminished protection against Omicron transmission and infection.
Clinical and commercial stage biopharmaceutical company
Sorrento Therapeutics Inc. (NASDAQ: SRNE, Forum) announced on Friday that its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.
The company stated that STI-1558’s antiviral activity against Omicron has also been tested in a cell-based neutralization assay. In VeroE6 cells challenged with Omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent activity to that seen against the Delta variant (EC50 value, 370 nM). Notably, in an Omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved nirmatrelvir showed no inhibition.
For full details on this news, click
here.